CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV), a biomaterials company with innovative technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that it has closed an underwritten public offering of 12,175,000 shares of common stock and warrants to purchase up to an aggregate of 6,087,500 shares of common stock, at a price of $1.15 per share of common stock and $0.00001 per warrant. The warrants have a per share exercise price of $1.4375, 125% of the public offering price of the common stock, are exercisable immediately, and expire five years from the date of issuance. In addition, the underwriter exercised its entire over-allotment option to purchase an additional 1,826,250 shares of common stock and warrants to purchase an additional 913,125 shares of common stock.
Help employers find you! Check out all the jobs and post your resume.
